Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND -0.50%11 FCF Margin % is -4,487.50% as of Mar. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Vyome Holdings ranks worse than 87.05% on this metric.
The historical rank and industry rank for Vyome Holdings's FCF Margin % or its related term are showing as below:
HIND'
s FCF Margin % Range Over the Past 10 Years
Min: -3234.42 Med: -187.25 Max: -94.78
Current: -3234.42
During the past 4 years, the highest FCF Margin % of Vyome Holdings was -94.78%. The lowest was -3234.42%. And the median was -187.25%.
HIND's FCF Margin % is ranked worse than 87.05% of 950
companies
in the Biotechnology industry
Industry Median: -82.715
vs HIND: -3234.42
Vyome Holdings FCF Margin % Related Terms
Vyome Holdings FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a FCF Margin % of -4,487.50% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #827 out of 950 companies in the Biotechnology industry, placing it in the top 87.1%.
Is Vyome Holdings' FCF Margin % too high?
Vyome Holdings' current FCF Margin % is -4,487.50%. Based on the distribution chart, Vyome Holdings ranks #827 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' FCF Margin % compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #827 out of 950 companies for FCF Margin %. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current FCF Margin % is -4,487.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current FCF Margin % of -4,487.50%. The current FCF Margin % is -4,487.50%. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current FCF Margin % is -4,487.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
